EN DE

Aurora Optoelectronics Co (600666) Fair Value & Analysis

Healthcare · CN · Market cap 10.6B CNY

AO Aurora Optoelectronics Co 600666 · SHG
Price¥3.85
Fair Value¥0.8700
Upside-77.4%
Quality56/100
Watch Aurora Optoelectronics Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Highly profitable · 28.7% net margin
Low debt · negative free cash flow
Trails peers (3/11)
Narrow moat 42/100
Evidence: Medium Range ¥0.6600 – ¥1.09 Share as image

Fair value as of: Aug 9, 2026

From 10 valuation models · updated yesterday

Share price +11.0% over the past month.

A solid business, but screening 77% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥1.09). The favourable scenario is already priced in.
  • Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥7.16 ¥1.09 Fair Value ¥0.8700 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.

How to read this chart

60‑month range ¥1.09 – ¥7.16 · fair‑value band ¥0.6600 – ¥1.09 · the ¥3.85 price screens above the ¥0.8700 fair value. Dashed = 300-day average. As of Aug 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aurora Optoelectronics Co (600666) currently trades at ¥3.85, while our model-based Fair Value estimate is ¥0.8700, implying the stock looks roughly 77.4% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Aurora Optoelectronics Co generated revenue of 487M CNY at a net margin of 28.7%. Revenue grew 22.7% year over year. It earns a return on equity of 13.5%. The balance sheet holds a net cash position of 84.1M CNY. Fundamentals as of Aug 9, 2026

Our scenario range runs from ¥0.6600 (bear case) to ¥1.09 (bull case); at ¥3.85, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 52% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -77%, 600666 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Residual Income ¥0.3600 ¥0.4500 ¥1.12 76
Growth-Adj P/E ¥0.6300 ¥0.9000 ¥1.17 68
P/E Multiple ¥0.8100 ¥1.08 ¥1.35 63
All 10 models by family
DCF Models
Owner Earnings ¥1.02 ¥1.48 ¥2.15 31
Earnings-Based
Graham-Dodd ¥0.3500 ¥0.9000 ¥1.17 54
PEG = 1.0 ¥0.1700 ¥0.2400 ¥0.3100 46
Multiples
P/E Multiple ¥0.8100 ¥1.08 ¥1.35 63
P/S Multiple ¥0.2500 ¥0.3400 ¥0.4200 58
P/B Multiple ¥0.6600 ¥0.8700 ¥1.09 55
EV/EBITDA ¥0.4700 ¥0.6200 ¥0.7600 54
Asset-Based
NCAV (Graham) ¥0.1800 ¥0.2400 ¥0.3600 50
Economic Profit
Residual Income ¥0.3600 ¥0.4500 ¥1.12 76
Growth Earnings
Growth-Adj P/E ¥0.6300 ¥0.9000 ¥1.17 68

Widest divergence: DCF Models (¥1.48) versus Earnings-Based (¥0.2400). Highest evidence: Residual Income (76).

Key figures & financial health

Revenue (TTM) 487M CNY
Revenue growth (YoY) +22.7%
Net margin 28.7%
Return on equity 13.5%
Free cash flow −18.9M CNY FY2025
P/E ratio 77.0
More key figures
Operating margin -4.7%
EPS (TTM) ¥0.0500
EPS growth (YoY) +552%
Net cash 84.1M CNY FY2024

Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 56/100

Of which business quality 54 · Market factors (momentum, volatility) 38

Profitability 43
Margins and returns on capital today
Quality Growth 92
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Aurora Optoelectronics Co.,Ltd. engages in the production and sale of sapphire crystal materials in China. The company offers Sapphire crystal rod, wafer, substrate, window, and single crystal furnace, as well as LED Filament used for LED lighting and display, and consumer electronics window.

Full company description

Aurora Optoelectronics Co.,Ltd. engages in the production and sale of sapphire crystal materials in China. The company offers Sapphire crystal rod, wafer, substrate, window, and single crystal furnace, as well as LED Filament used for LED lighting and display, and consumer electronics window. It also provides computing power leasing, integrated intelligent computing center, AI application investment and cooperation, and industry solutions. The company was incorporated in 2006 and is headquartered in Harbin, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aurora Optoelectronics Co reported revenue of ¥465M in FY2025 versus ¥700M in FY2021, a compound −9.7%/yr. Reported net income was ¥141M in FY2025.

Growth Quality 30/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
465M CNY
Latest YoY
+27.1%
Avg. growth/yr (3Y)
−4.3%
Avg. growth/yr (5Y)
−2.2%
Avg. growth/yr (32Y)
+2.7%
Revenue −9.7%/yr
FY21 ¥700M
FY22 ¥531M
FY23 ¥328M
FY24 ¥366M
FY25 ¥465M
Net income
FY21 −¥483M
FY22 ¥60.5M
FY23 −¥675M
FY24 −¥171M
FY25 ¥141M

600666 screens 77% overvalued. Compare with Eli Lilly and Company →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Aurora Optoelectronics Co Fair Value". https://www.fairvalue-calculator.com/stock/600666

Peer Group

Drug Manufacturers - General · 76 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Below median
Fair Value upside −77% · Bottom 25%
Return on equity (TTM) 13% · Above median
Return on assets -1% · Bottom 25%
Net margin (TTM) 29% · Top 25%
Operating margin (TTM) -5% · Bottom 25%
Revenue growth 23% · Top 25%
Debt / equity 0.19× · Higher than median

Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 77.0× · Pricier than 75% of peers
P/B 10.60× · Pricier than 75% of peers
P/S (TTM) 21.73× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 100 · sector 24
PAST 54 · sector 50
HEALTH 91 · sector 94
DIVIDEND 0 · sector 46

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,182 $396.77 -66%
Johnson & Johnson, JNJ $257.59 $169.04 -34%
AbbVie Inc ABBV $254.49 $67.72 -73%
Roche Holding 1RO €392.80 €226.68 -42%
Merck & Co MRK €108.08 €121.54 +12%
Novartis AG NVSN 2,742 MXN 2,379 MXN -13%
AstraZeneca PLC AZN $171.61 $129.54 -25%
Novo Nordisk A/S NOVOB kr 329.90 kr 409.46 +24%
Amgen Inc AMGN $363.39 $252.02 -31%
Sanofi SNYN 770.00 MXN 1,251 MXN +63%

Compare Aurora Optoelectronics Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Aurora Optoelectronics Co (600666) overvalued or undervalued?
As of Aug 9, 2026, our model estimates a fair value of ¥0.8700 versus a price of ¥3.85, about −77% (overvalued).
What is the fair value of 600666?
Our model-based fair value for Aurora Optoelectronics Co is ¥0.8700 (as of Aug 9, 2026), built from audited fundamentals. The current price is ¥3.85.
What is the quality score of 600666?
Aurora Optoelectronics Co has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Aurora Optoelectronics Co (600666)?
Aurora Optoelectronics Co reported trailing-twelve-month revenue of about 487M CNY (latest available figure, as of Aug 9, 2026).
What is the net profit margin of 600666?
The net profit margin of Aurora Optoelectronics Co is about 28.7%, meaning it keeps roughly 28.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Aurora Optoelectronics Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.